SNPX Logo

Synaptogenix, Inc. (SNPX) 

NASDAQ$2.8
Market Cap
$3.8M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
849 of 924
Rank in Industry
482 of 527

SNPX Insider Trading Activity

SNPX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00
Sells
$00

Related Transactions

No records found

About Synaptogenix, Inc.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; …

Insider Activity of Synaptogenix, Inc.

Over the last 12 months, insiders at Synaptogenix, Inc. have bought $0 and sold $0 worth of Synaptogenix, Inc. stock.

On average, over the past 5 years, insiders at Synaptogenix, Inc. have bought $165,600 and sold $190,375 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $83,000 was made by Silverman Joshua (director) on 2021‑06‑14.

List of Insider Buy and Sell Transactions, Synaptogenix, Inc.

2022-12-16SaleSilverman Joshuadirector
19,012
0.2656%
$1.17$22,280-30.83%
2022-12-16SaleAlkon Daniel L.President and CSO
19,688
0.2751%
$1.17$23,072-30.83%
2022-12-16SaleWEINSTEIN ROBERTChief Financial Officer
27,000
0.3773%
$1.17$31,641-30.83%
2022-12-16SaleTUCHMAN ALAN JChief Executive Officer
27,000
0.3773%
$1.17$31,641-30.83%
2022-12-16SaleSinger William S.director
27,000
0.3773%
$1.17$31,641-30.83%
2022-12-16SaleSCHECHTER JONATHANdirector
20,250
0.2829%
$1.17$23,731-30.83%
2022-12-16SaleBernstein Brucedirector
22,500
0.3144%
$1.17$26,368-30.83%
2021-06-14PurchaseSilverman Joshuadirector
10,000
0.2577%
$8.30$83,000-3.58%
2021-06-14PurchaseAlkon Daniel L.Chief Scientific Officer
10,000
0.2565%
$8.26$82,600-3.58%
Total: 9

Insider Historical Profitability

<0.0001%
Silverman Joshuadirector
38238
2.8207%
$107,066.4011<0.0001%
Alkon Daniel L.President and CSO
35546
2.6221%
$99,528.8011<0.0001%

Historical Insider Profitability vs. Competitors

$18,881,323
88
-48.96%
$5.9M
$296,936
37
-18.12%
$3.46M
$960,082
17
-6.29%
$3.37M
$1,558,469
16
-26.98%
$4.79M
$139,855
11
-32.84%
$5.37M

SNPX Institutional Investors: Active Positions

Increased Positions2+28.57%12,995+510.81%
Decreased Positions<1-14.29%1,005-39.5%
New Positions<1New10,844New
Sold Out Positions0Sold Out0Sold Out
Total Postitions8+14.29%14,534+471.31%

SNPX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Geode Capital Management, Llc$29.001.08%10,844+10,844New2024-12-31
Ubs Group Ag$9.000.32%3,238+2,151+197.88%2024-12-31
Tower Research Capital Llc (Trc)$1.000.03%266-1,005-79.07%2024-12-31
Morgan Stanley$00.01%9000%2024-12-31
Osaic Holdings, Inc.$0<0.01%3400%2024-12-31
Blackrock, Inc.$0<0.01%2900%2024-12-31
Acadian Asset Management Llc$0<0.01%2300%2024-12-31
Bank Of America Corp /De/$0<0.01%1000%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.